Seeking high-priority mutations enabling successful antibody-breeding: systematic analysis of a mutant that gained over 100-fold enhanced affinity.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
16 03 2020
Historique:
received: 30 10 2019
accepted: 27 02 2020
entrez: 18 3 2020
pubmed: 18 3 2020
medline: 15 12 2020
Statut: epublish

Résumé

"Antibody-breeding" has provided therapeutic/diagnostic antibody mutants with greater performance than native antibodies. Typically, random point mutations are introduced into the V

Identifiants

pubmed: 32179767
doi: 10.1038/s41598-020-61529-7
pii: 10.1038/s41598-020-61529-7
pmc: PMC7075871
doi:

Substances chimiques

Complementarity Determining Regions 0
Single-Chain Antibodies 0
Estradiol 4TI98Z838E

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

4807

Références

Gibney, E., Noorden, R. V., Ledford, H., Castelvecchi, D. & Warren, M. Nobel for test-tube evolution. Nature 562, 176 (2018).
pubmed: 30301984 doi: 10.1038/d41586-018-06753-y
Handbook of therapeutic antibodies (ed Dübel, S.) (Wiley-Blackwell, 2004).
Bradbury, A. R. M., Sidhu, S., Dübel, S. & McCafferty, J. Beyond natural antibodies: the power of in vitro display technologies. Nat. Biotechnol. 29, 245–254 (2011).
pubmed: 21390033 pmcid: 3057417 doi: 10.1038/nbt.1791
Chiu, M. L. & Gilliland, G. L. Engineering antibody therapeutics. Curr. Opin. Struct.Biol. 38, 163–173 (2016).
pubmed: 27525816 doi: 10.1016/j.sbi.2016.07.012
Kennedy, P. J., Oliveira, C., Granja, P. L. & Sarmento, B. Monoclonal antibodies: technologies for early discovery and engineering. Crit. Rev. Biotechnol. 38, 394–408 (2018).
pubmed: 28789584 doi: 10.1080/07388551.2017.1357002
Skerra, A. & Plückthun, A. Assembly of a functional immunoglobulin Fv fragment in Escherichia coli. Science 240, 1038–1041 (1988).
pubmed: 3285470 doi: 10.1126/science.3285470
Bird, R. E. et al. Single-chain antigen-binding proteins. Science 242, 423–426 (1988).
pubmed: 3140379 doi: 10.1126/science.3140379
Smith, G. P. & Petrenko, V. A. Phage display. Chem. Rev. 97, 391–410 (1997).
pubmed: 11848876 doi: 10.1021/cr960065d
Phage display (eds Clackson, T. & Lowman, H. B.) (Oxford University Press, 2004).
Plückthun, A. Ribosome display: a perspective. Methods Mol. Biol. 805, 3–28 (2012).
pubmed: 22094797 doi: 10.1007/978-1-61779-379-0_1
Gai, S. A. & Wittrup, K. D. Yeast surface display for protein engineering and characterization. Curr. Opin. Struct. Biol. 17, 467–473 (2007).
pubmed: 17870469 pmcid: 4038029 doi: 10.1016/j.sbi.2007.08.012
Kobayashi, N. et al. Anti-estradiol-17β single-chain Fv fragments: generation, characterization, gene randomization, and optimized phage display. Steroids 73, 1485–1499 (2008).
pubmed: 18824188 doi: 10.1016/j.steroids.2008.08.009
Kobayashi, N. et al. Two-step in vitro antibody affinity maturation enables estradiol-17β assays with more than 10-fold higher sensitivity. Anal. Chem. 82, 1027–1038 (2010).
pubmed: 20047279 doi: 10.1021/ac902283n
Oyama, H., Yamaguchi, S., Nakata, S., Niwa, T. & Kobayashi, N. “Breeding” diagnostic antibodies for higher assay performance: a 250-fold affinity-matured antibody mutant targeting a small biomarker. Anal. Chem. 85, 4930–4937 (2013).
pubmed: 23631394 doi: 10.1021/ac3037602
Oyama, H. et al. One-shot in vitro evolution generated an antibody fragment for testing urinary cotinine with more than 40-fold enhanced affinity. Anal. Chem. 89, 988–995 (2017).
pubmed: 27983781 doi: 10.1021/acs.analchem.6b04332
Oyama, H. et al. A single-step “breeding” generated a diagnostic anti-cortisol antibody fragment with over 30-fold enhanced affinity. Biol. Pharm. Bull. 40, 2191–2198 (2017).
pubmed: 29199242 doi: 10.1248/bpb.b17-00633
Morita, I. et al. Antibody fragments for on-site testing of cannabinoids generated via in vitro affinity maturation. Biol. Pharm. Bull. 40, 174–181 (2017).
pubmed: 28154257 doi: 10.1248/bpb.b16-00669
Leung, D. W., Chen, E. & Goeddel, D. V. A method for random mutagenesis of a defined DNA segment using a modified polymerase chain reaction. Technique 1, 11–15 (1989).
Boder, E. T., Midelfort, K. S. & Wittrup, K. D. Directed evolution of antibody fragments with monovalent femtomolar antigen-binding affinity. Proc. Natl. Acad. Sci. USA 97, 10701–10705 (2000).
pubmed: 10984501 doi: 10.1073/pnas.170297297 pmcid: 10984501
Barderas, R., Desmet, J., Timmerman, P., Meloen, R. & Casal, J. I. Affinity maturation of antibodies assisted by in silico modeling. Proc. Natl. Acad. Sci. USA 105, 9029–9034 (2008).
pubmed: 18574150 doi: 10.1073/pnas.0801221105
Lippow, S. M., Wittrup, K. D. & Tidor, B. Computational design of antibody affinity improvement beyond in vivo maturation. Nat. Biotechnol. 25, 1171–1176 (2007).
pubmed: 17891135 pmcid: 2803018 doi: 10.1038/nbt1336
Sormanni, P., Aprile, F. A. & Vendruscolo, M. Third generation antibody discovery methods: in silico rational design. Chem. Soc. Rev. 47, 9137–9157 (2018).
pubmed: 30298157 doi: 10.1039/C8CS00523K
Cannon, D. A. et al. Experimentally guided computational antibody affinity maturation with de novo docking, modelling and rational design. PLoS Comput. Biol. 15, e1006980 (2019).
pubmed: 31042706 pmcid: 6513101 doi: 10.1371/journal.pcbi.1006980
Knappik, A. & Plückthun, A. An improved affinity tag based on the FLAG
pubmed: 7530459
Kabat, E. A., Wu, T. T., Perry, H. M., Gottesman, K. S. & Foeller, C. Sequences of Proteins of Immunological Interest. U.S. Department of Health and Human Services, National Institutes of Health (U.S. Government Printing Office, 1991).
Wu, T. T., Johnson, G. & Kabat, E. A. Length distribution of CDRH3 in antibodies. Proteins: Struct. Funct. Genet. 16, 1–7 (1993).
doi: 10.1002/prot.340160102
Collis, A. V. J., Brouwer, A. P. & Martin, A. C. R. Analysis of the antigen combining site: correlations between length and sequence composition of the hypervariable loops and the nature of the antigen. J. Mol. Biol. 325, 337–354 (2003).
pubmed: 12488099 doi: 10.1016/S0022-2836(02)01222-6
Scatchard, G. The attractions of proteins for small molecules and ions. Ann. N. Y. Acad. Sci. 51, 660–672 (1949).
doi: 10.1111/j.1749-6632.1949.tb27297.x
Hosoda, H., Kobayashi, N. & Nambara, T. Effect of bridge heterologous combination on sensitivity in enzyme immunoassay for 11-deoxycortisol. Chem. Pharm. Bull. 31, 953–958 (1983).
doi: 10.1248/cpb.31.953
Hosoda, H., Kobayashi, N., Ishii, N. & Nambara, T. Bridging phenomena in steroid immunoassays. The effect of bridge length on sensitivity in enzyme immunoassay. Chem. Pharm. Bull. 34, 2105–2111 (1986).
pubmed: 3527456 doi: 10.1248/cpb.34.2105
Hoogenboom, H. R., Marks, J. D., Griffiths, A. D. & Winter, G. Building antibodies from their genes. Immunol. Rev. 130, 41–68 (1992).
pubmed: 1286871 doi: 10.1111/j.1600-065X.1992.tb01520.x
Barbas, C. F. III, Bain, J. D., Hoekstra, D. M. & Lerner, R. A. Semisynthetic combinatorial antibody libraries: a chemical solution to the diversity problem. Proc. Natl. Acad. Sci. USA 89, 4457–4461 (1992).
pubmed: 1584777 doi: 10.1073/pnas.89.10.4457
Griffiths, A. D. et al. Isolation of high affinity human antibodies directly from large synthetic repertoires. EMBO J. 13, 3245–3260 (1994).
pubmed: 8045255 pmcid: 395221 doi: 10.1002/j.1460-2075.1994.tb06626.x
Valjakka, J. et al. Crystal structure of an in vitro affinity- and specificity-matured anti-testosterone Fab in complex with testosterone. J. Biol. Chem. 277, 44021–44027 (2002).
pubmed: 12196551 doi: 10.1074/jbc.M208392200
Fellouse, F. A. et al. Molecular recognition by a binary code. J. Mol. Biol. 348, 1153–1162 (2005).
pubmed: 15854651 doi: 10.1016/j.jmb.2005.03.041
Oliva, B., Bates, P. A., Querol, E., Avilés, F. X. & Sternberg, M. J. E. Automated classification of antibody complementarity determining region 3 of the heavy chain (H3) loops into canonical forms and its application to protein structure prediction. J. Mol. Biol. 279, 1193–1210 (1998).
pubmed: 9642095 doi: 10.1006/jmbi.1998.1847
Angelo, S. D. et al. Many routes to an antibody heavy-chain CDR3: necessary, yet insufficient, for specific binding. Front. Immunol. 9, 395 (2018).
pubmed: 29568296 pmcid: 5852061 doi: 10.3389/fimmu.2018.00395
Kobayashi, N. & Oyama, H. Antibody engineering toward high-sensitivity high-throughput immunosensing of small molecules. Analyst 136, 642–651 (2011).
pubmed: 21152564 doi: 10.1039/C0AN00603C
Dennis, M. S. & Lowman, H. B. Phage selection strategies for improved affinity and specificity of proteins and peptides. In Phage display (Ref. 9).
Derda, R. et al. Diversity of phage-displayed libraries of peptides during panning and amplification. Molecules 16, 1776–1803 (2011).
pubmed: 21339712 pmcid: 6259649 doi: 10.3390/molecules16021776
Chothia, C. et al. Conformations of immunoglobulin hypervariable regions. Nature 342, 877–883 (1989).
pubmed: 2687698 doi: 10.1038/342877a0
Al-Lazikani, B., Lesk, A. M. & Chothia, C. Standard conformations for the canonical structures of immunoglobulins. J. Mol. Biol. 273, 927–948 (1997).
pubmed: 9367782 doi: 10.1006/jmbi.1997.1354
Sharon, J. Structural correlates of high antibody affinity: three engineered amino acid substitutions can increase the affinity of an anti-p-azophenylarsonate antibody 200-fold. Proc. Natl. Acad. Sci. USA 87, 4814–4817 (1990).
pubmed: 2352950 doi: 10.1073/pnas.87.12.4814
Schildbach, J. F. et al. Altered hapten recognition by two anti-digoxin hybridoma variants due to variable region point mutations. J. Biol. Chem. 266, 4640–4647 (1991).
pubmed: 1999439
Vargas-Madrazo, E., Lara-Ochoa, F. & Almagro, J. C. Canonical structure repertoire of the antigen-binding site of immunoglobulins suggests strong geometrical restrictions associated to the mechanism of immune recognition. J. Mol. Biol. 254, 497–504 (1995).
pubmed: 7490765 doi: 10.1006/jmbi.1995.0633
Siegel, R. W., Baugher, W., Rahn, T., Drengler, S. & Tyner, J. Affinity maturation of tacrolimus antibody for improved immunoassay performance. Clin. Chem. 54, 1008–1017 (2008).
pubmed: 18403566 doi: 10.1373/clinchem.2007.097352
Jirholt, P., Ohlin, M., Borrebaeck, C. A. K. & Söderlind, E. Exploiting sequence space: shuffling in vivo formed complementarity determining regions into a master framework. Gene 215, 471–476 (1998).
pubmed: 9714846 doi: 10.1016/S0378-1119(98)00317-5
Schneider, C. A., Rasband, W. S. & Eliceiri, K. W. NIH Image to ImageJ: 25 years of image analysis. Nat. Methods 9, 671–675 (2012).
pubmed: 5554542 pmcid: 5554542 doi: 10.1038/nmeth.2089
Oyama, H., Yamaguchi, S., Nakata, S., Niwa, T. & Kobayashi, N. Correction to “Breeding” diagnostic antibodies for higher assay performance: a 250-fold affinity-matured antibody mutant targeting a small biomarker. Anal. Chem. 91, 15325 (2019).
pubmed: 31710207 doi: 10.1021/acs.analchem.9b04966
Guex, N., Diemand, A. & Peitsch, M. C. Protein modelling for all. Trends Biochem. Sci. 24, 364–367 (1999).
pubmed: 10470037 doi: 10.1016/S0968-0004(99)01427-9
Grosdidier, A., Zoete, V. & Michielin, O. SwissDock, a protein-small molecule docking web service based on EADock DSS. Nucleic Acids Res. 39, W270–W277 (2011).
DeLano, W. The PyMOL Molecular Graphics System; DeLano Scientific LLC: Palo Alto, CA, USA, 2008. Available at, http://www.pymol.org .

Auteurs

Hiroyuki Oyama (H)

Kobe Pharmaceutical University, 4-19-1, Motoyama-Kitamachi, Higashinada-ku, Kobe, 658-8558, Japan.

Yuki Kiguchi (Y)

Kobe Pharmaceutical University, 4-19-1, Motoyama-Kitamachi, Higashinada-ku, Kobe, 658-8558, Japan.

Izumi Morita (I)

Kobe Pharmaceutical University, 4-19-1, Motoyama-Kitamachi, Higashinada-ku, Kobe, 658-8558, Japan.

Chika Yamamoto (C)

Kobe Pharmaceutical University, 4-19-1, Motoyama-Kitamachi, Higashinada-ku, Kobe, 658-8558, Japan.

Yuka Higashi (Y)

Kobe Pharmaceutical University, 4-19-1, Motoyama-Kitamachi, Higashinada-ku, Kobe, 658-8558, Japan.

Miku Taguchi (M)

Kobe Pharmaceutical University, 4-19-1, Motoyama-Kitamachi, Higashinada-ku, Kobe, 658-8558, Japan.

Tatsuya Tagawa (T)

Kobe Pharmaceutical University, 4-19-1, Motoyama-Kitamachi, Higashinada-ku, Kobe, 658-8558, Japan.

Yuri Enami (Y)

Kobe Pharmaceutical University, 4-19-1, Motoyama-Kitamachi, Higashinada-ku, Kobe, 658-8558, Japan.

Yuriko Takamine (Y)

Kobe Pharmaceutical University, 4-19-1, Motoyama-Kitamachi, Higashinada-ku, Kobe, 658-8558, Japan.

Hanako Hasegawa (H)

Kobe Pharmaceutical University, 4-19-1, Motoyama-Kitamachi, Higashinada-ku, Kobe, 658-8558, Japan.

Atsuko Takeuchi (A)

Kobe Pharmaceutical University, 4-19-1, Motoyama-Kitamachi, Higashinada-ku, Kobe, 658-8558, Japan.

Norihiro Kobayashi (N)

Kobe Pharmaceutical University, 4-19-1, Motoyama-Kitamachi, Higashinada-ku, Kobe, 658-8558, Japan. no-kobay@kobepharma-u.ac.jp.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH